What Hartenberg Capital does

Hartenberg Capital is the general partner and administrator of Hartenberg Holding, a Prague-based private equity firm founded in 2013 that invests exclusively from founder commitments — approximately EUR 300 million — to acquire majority stakes in established Central European businesses with enterprise values typically between EUR 40 million and EUR 200 million. The firm pursues a buy-and-build consolidation strategy across healthcare (FutureLife, an IVF/genetics network with 40+ clinics in 12+ countries performing 55,000+ cycles annually, scaling to 74,000+ with the announced Bahceci acquisition), e-commerce (Enterstore group consolidating niche consumer brands including Kinderkraft, Astratex, Miss Mary of Sweden, Sportega, Ovečkárna, and UNUO), aviation MRO (Avia Prime, currently being divested via the Adria Tehnika sale to easyJet and completed JAT Tehnika exit), FMCG (Good Food, rice and corn cake producer with 4x sales growth since entry), pharma (Imunoglukan immune support supplements), retail (Flamengo florist chain with 190+ outlets in Czech Republic and Slovakia), and real estate development (partnerships with Corwin, JRD, Ikonix, and Yuzu). As of December 31, 2025, the consolidated portfolio generated EUR 940 million in sales and EUR 130 million in EBITDA across 19 countries, with EUR 700 million in equity value and 5,900 employees; 61 acquisitions have been completed to date.

The firm is structured around founder equity rather than external LP fundraising. Beneficial owners of Hartenberg Holding include Andrej Babiš and Jozef Janov, while Jozef Janov and Libor Němeček are the beneficial owners of Hartenberg Capital; key investment professionals hold stakes tied to portfolio performance. CVC Capital Partners Fund VIII became a co-controlling shareholder of FutureLife in December 2021, validating the platform thesis and providing healthcare-specific expertise. Revenue mechanics for Hartenberg itself are derived from equity appreciation, dividends, and exit proceeds rather than management fees; the firm's distributed capital across sectors provides risk diversification absent in single-thesis PE platforms. Distribution spans direct-to-consumer e-commerce (own storefronts and marketplaces such as Amazon), physical retail (Flamengo outlets), enterprise MRO services to commercial airlines (Lufthansa Group, Air France, SAS, EasyJet, Finnair, Norwegian, Nordstar, TUI), and patient-facing healthcare clinics.

No unifying technology platform or AI/ML capability is described. Deal sourcing relies on founder/management networks and co-investor relationships rather than marketed demand generation. Recent strategic activity is split between offensive consolidation (FutureLife's Bahceci acquisition extending IVF reach into southeastern Europe; Enterstore's 2024 acquisitions of Kinderkraft and Miss Mary adding EUR 100M+ revenue) and defensive divestiture of the aviation MRO segment (Adria Tehnika to easyJet, JAT Tehnika completion). The European Commission has separately opened an investigation into conflict-of-interest safeguards across companies linked to Andrej Babiš, including Hartenberg Holding, which represents an unresolved governance risk per third-party reporting.

Name

Hartenberg Capital

Legal name

Hartenberg Capital, s.r.o.

Website

https://hartenbergcapital.com

Company type

Private

Founded year

2013

Operating status

Operating

Short description

Prague-based Hartenberg Capital is a private equity firm founded in 2013 that deploys founder capital (EUR 300M) for buy-and-build investments in Central European market leaders across healthcare, e-commerce, aviation MRO, FMCG, and real estate; portfolio sales reach EUR 940 million.

Ownership category

akta.pro rank

Product category

Private Equity Investment Management

NAICS

All Other Financial Investment Activities (52399)

SIC

Investors, Nec (6799)

akta.pro primary industry

Captive CVC Fund (Dedicated corporate fund structure) (FSANAHAB)

akta.pro secondary industries

Strategic / Balance-Sheet CVC (On-balance-sheet investing) (FSANAHAA), Joint Venture CVC / Consortium Funds (Multi-corporate) (FSANAHAE)

Keywords

• Private equity investing
• Central European buyouts
• Buy-and-build strategy
• Portfolio investment management
• Majority stake acquisitions

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Private equity returns and portfolio dividends: Hartenberg generates returns through equity appreciation, dividends, and exit proceeds from its portfolio companies. The firm invests its own capital (EUR 300 million in founder commitments) and supports management teams to drive growth, with typical holding periods over five years. Revenue is realized through exit events and ongoing portfolio company performance.
2. Portfolio company revenues (consolidated scale): Hartenberg Holding's portfolio companies generate approximately EUR 940 million in sales and EUR 130 million in EBITDA across 19 countries. The diverse portfolio spans healthcare (IVF/fertility), e-commerce, FMCG, aviation MRO, and real estate.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels3 records

Core offering

Hartenberg Capital is a private equity investment firm that acquires majority stakes in market-leading companies primarily across Central Europe, with enterprise values between EUR 40 million and EUR 200 million. The firm pursues a buy-and-build consolidation strategy across healthcare (IVF/fertility), e-commerce, FMCG, aviation MRO, retail floristry, pharma, and real estate development, backing management teams with capital, operational expertise, and cross-border expansion support.

Product overview

Hartenberg Capital is a private equity investment firm serving as the General Partner and Administrator of Hartenberg Holding. The firm operates as a platform holding investments across multiple sectors and portfolio companies rather than a single unified product. The portfolio includes: FutureLife (European IVF and genetics leader with 40+ clinics), Enterstore (e-commerce platform with brands including KinderKraft, Astratex, Ovečkárna, Unuo, Sportega, Miss Mary), Flamengo/Storge (florist retail), Imunoglukan (pharma/immune support), Good Food (FMCG/rice cakes), Avia Prime (aviation MRO), and real estate development partnerships (Corwin, JRD, Ikonix, Yuzu). The firm also manages the HARTENBERG INVESTMENT FUND SICAV for public equity investments.

Differentiator

Problem solved

Functional benefit

Brands

• FutureLife: European leader in IVF and genetics services with 60+ clinics across 16 countries
• Enterstore
• Flamengo
• ASTRATEX
• Kinderkraft
• HARTENBERG INVESTMENT FUND SICAV

Products and services

• FutureLife

Quantifiable outcome

• Over 55,000 IVF cycles performed annually across FutureLife's network (growing to 74,000+ after Bahceci acquisition)
• +6 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Twelve partnerships are on record, tiered core and secondary.

• JAT Tehnika buyer (unspecified new owner)coreOthers · 8 May 2026Hartenberg Holding, through its subsidiary Avia Prime, completed the sale of JAT Tehnika — one of the leading aircraft MRO providers in the Belgrade region. The transaction marked a successful exit from the Serbian MRO investment. JAT Tehnika operated from Belgrade Nikola Tesla Airport specializing in base maintenance, line maintenance, and technical support for commercial aircraft.
• easyJetcoreOthers · 3 December 2025Hartenberg Holding signed an agreement to sell its portfolio company Adria Tehnika to easyJet, one of Europe's largest airlines. Adria Tehnika operates a five-bay base maintenance facility at Ljubljana Airport and has provided heavy maintenance for the easyJet fleet for many years. The acquisition is expected to complete in Q1/2026.
• Bahceci GroupcoreStrategic or Co-development Partner · 12 May 2025FutureLife reached agreement to acquire a stake in Bahceci Group, which operates 6 clinics in Turkey and international centers in Bosnia & Herzegovina, Bulgaria, and Kosovo. Bahceci has helped over 100,000 patients from more than 100 countries and performs over 18,000 IVF cycles annually. The transaction would bring FutureLife's total IVF cycles to over 74,000 per annum across 12 countries.
• 4Kraft / KinderkraftcoreStrategic or Co-development Partner · 12 December 2024Enterstore acquired a majority stake in 4Kraft, leading European online retailer of baby products under the Kinderkraft brand. Founded in 2011 in Poznan, Poland, Kinderkraft has surpassed €100 million in annual sales across Western Europe and operates in Germany, France, UK, Poland, Spain, Italy, plus subsidiaries in China and the US. Founder Leszek Krysieniel remains as CEO and minority shareholder.
• Miss Mary of SwedensecondaryStrategic or Co-development Partner · 12 December 2024Enterstore acquired a majority stake in Miss Mary of Sweden, an international lingerie and swimwear brand established in 1957, operating in Germany, Netherlands, Sweden, Denmark, and the US. The acquisition strengthened Enterstore's portfolio of niche e-commerce brands and international presence.
• UNUO / unuodesignsecondaryStrategic or Co-development Partner · 5 May 2023Enterstore acquired a majority stake in unuodesign, which operates the UNUO e-commerce brand for children's clothing made in-house. The founder Petra Plemlová retained a minority stake and continues as CEO. The transaction was Enterstore's fourth e-commerce investment, supporting UNUO's expansion to Germany and other markets with a goal to triple revenue within five years.
• Institut MarquèscoreStrategic or Co-development Partner · 4 October 2022FutureLife acquired Institut Marquès, a leading IVF company founded over a century ago and headquartered in Barcelona, Spain. Institut Marquès operates 3 clinics in Spain and 2 in Italy, performing over 3,000 egg collections per year. Dr. Marisa López-Teijón remains as founder and Medical Director; Dr. Borja Marquès-Teijón continues as medical director and shareholder. The acquisition extended FutureLife's presence to Spain and Italy.
• CorwincoreStrategic or Co-development Partner · 1 November 2021Hartenberg Holding partnered with Slovak developer Corwin (described as the 'greenest' developer in Slovakia & Slovenia) for joint real estate development. The partnership comprises multiple residential and office projects across Slovenia and Slovakia, including Vilharia, Nordika, Nove Vysocany, Kolinska, Linhartov Kvart, and Racianska. Hartenberg holds 45-50% stakes; Corwin leads with 50-55%. Projects focus on sustainable urban development in Ljubljana and Bratislava.
• Nij GroupcoreStrategic or Co-development Partner · 1 November 2021FutureLife entered a strategic partnership with Nij Group, a leading IVF group in the Netherlands. This partnership marked FutureLife's entry into the Dutch market, enabling knowledge sharing, best practices, and resource sharing between the organizations to benefit patients through improved care and access to advanced reproductive technologies.
• OvečkárnasecondaryStrategic or Co-development Partner · 1 January 2021Enterstore initially acquired 60% of Ovečkárna in 2021, then increased to 90% in 2023 when founder Martin Bernátek sold his remaining stake. Ovečkárna operates sheep wool products e-commerce in Czech Republic, Slovakia, Hungary, Romania, and Germany under the Vlnka brand. The acquisition supports Enterstore's strategy of building a network of niche European e-commerce brands.
• JRDcoreStrategic or Co-development Partner · 12 March 2020Hartenberg formed a long-term strategic partnership with JRD (Jan Řežáb's residential development holding) for Prague-based real estate projects. Hartenberg provides majority equity financing on a project-by-project basis; JRD leads operational management. Projects include Císařská Vinice, Kladno, Barandov, Hamry, and Horní Plána. Hartenberg holds 85% stakes; JRD holds 15%.
• Nova Vita and OvumiacoreStrategic or Co-development Partner · 14 October 2019FutureLife acquired a majority stake in Nova Vita Kliinik (Estonia) and Ovumia (Finland), leading fertility clinic groups operating four clinics across Tallinn, Helsinki, Tampere, and Jyväskylä. Nova Vita and Ovumia leaders continue under FutureLife; Pekka Sillanaukee remains as CEO. The acquisition expanded FutureLife to 7 European countries with 29 clinics and over 29,000 treatment cycles annually.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Mid Europa Partners: Central European mid-market private equity firm that focuses on buy-and-build in the same geographies and ticket sizes (EUR 40M-200M EV range) as Hartenberg, with comparable sector breadth across consumer/retail and healthcare.
• CVC Capital Partners: Global private equity firm that is already a co-controlling investor alongside Hartenberg in FutureLife, operates the same pan-European mid-to-large cap buy-out model, and is a competitive counterparty for healthcare and consumer deals in Hartenberg's range.

Broad incumbents

• Advent International: Large global buy-out firm with deep European and Central European presence, active in healthcare services (including fertility) and consumer/retail, overlapping Hartenberg's deal universe at the upper end of its ticket sizes.
• EQT Partners: Swedish-rooted global private equity investor with significant healthcare and consumer practices in Europe; competes for the same pan-European buy-and-build platforms that Hartenberg targets through FutureLife and Enterstore.
• Cinven: Pan-European private equity firm with established healthcare and consumer portfolios, comparable in holding periods, ticket size and operating-partner model to Hartenberg's approach.
• Permira: Global private equity firm with strong European consumer and healthcare exposure; competes for larger healthcare services platforms and e-commerce/D2C roll-ups that overlap Hartenberg's investment strategy.
• KKR (European Private Equity): Global alternative asset manager with substantial European mid-to-large cap private equity activity, often co-investing with or competing against Hartenberg's network on healthcare and consumer buy-outs in the region.
• Bridgepoint Group: European mid-market private equity firm with comparable ticket sizes, healthcare and consumer focus, and pan-European consolidation strategy that overlaps Hartenberg's Central European focus.

Regional players

• Genesis Private Equity Fund: Czech-based private equity firm investing alongside management teams in Central European SMEs, overlapping Hartenberg's domestic deal flow and ticket range in the Czech Republic.
• Jet Investment: Central European private equity group focused on buyouts in the Czech Republic, Slovakia and neighboring countries, directly competing for the same SMB and mid-market buy-and-build opportunities as Hartenberg.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hartenberg-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hartenberg Capital